

Neuland Laboratories Limited
11th floor (5th level), Phoenix IVY Building,
Plot No.573A-III, Road No.82, Jubilee Hills,
Hyderabad-500033, Telangana, India.



CONTACT

040 6761 1600 / 6761 1700
neuland@neulandlabs.com
neulandlabs.com

August 1, 2024

To
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001

The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai - 400 001

Scrip Code: 524558

Scrip Code: NEULANLAB; Series: EQ

Dear Sir/Madam,

Sub: Press Release

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing Press Release on the Financial Results of the Company for the quarter ended June 30, 2024.

The Press Release is also being uploaded on the website of the Company at www.neulandlabs.com

This is for your information and records.

Yours sincerely,
For **Neuland Laboratories Limited**

Sarada Bhamidipati
Company Secretary

Encl: As above



Neuland Q1FY25 income at Rs.444.4 crore, up 21.7% YoY EBITDA at Rs.128.6 crore, up 29.5% YoY

Hyderabad, India, August 01, 2024 – Neuland Laboratories Limited (NLL) (NSE: NEULANDLAB; BSE:524558), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers located in around 80 countries, today announced financial results for the first quarter ended June 30, 2024.

Commenting on the performance Mr. Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, “We recorded our highest ever quarterly revenues in Q1FY25 led by growth in the CMS business even as we recorded healthy EBITDA margins. We continue to maintain that FY25 will be a year of normalisation of revenue growth and subsequently margins as we continue to invest for growth. We expect our business to regain momentum from FY26 onwards basis our visibility from our portfolio of projects and products.”

In addition, Mr. Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories added “The CMS revenues were driven by commercial molecules in line with our expectations as we outline our strategy over the years. As we evaluate our pipeline of projects and the flow of new projects, we remain enthusiastic on the strong potential of the CMS business over the long term. The GDS business continues to build on the strong base we have with quality focussed customers, even as our R&D team is working on an exciting set of molecules to add to our portfolio.”

Financial Summary

Particulars	Q1FY25	Q1FY24	YoY Growth (%)	Q4FY24	QoQ Growth (%)
Total Income	444.4	365.0	21.7%	390.4	13.8%
EBITDA	128.6	99.3	29.5%	112.2	14.7%
EBITDA margin (%)	28.9%	27.2%	174 bps	28.7%	21 bps
Exceptional Item	20.6*	-	-	-	-
PAT*	98.3	62.2	58.0%	67.6	45.5%
PAT margin (%)	22.1%	17.0%	510 bps	17.3%	480 bps
EPS (Basic) Rs.	76.6	48.5	58.0%	52.7	45.5%

*Q1FY25 Includes exceptional item of profit on transfer of investment property of Rs. 20.6 crores

Q1 FY25 Earnings Call

The company will conduct a one-hour Earnings call at **17:30 hrs. IST on Thursday, August 01, 2024** where the management will discuss the Company’s performance and answer questions from participants. To participate in this conference call, please register on the link below:

[Diamond Pass Registration Link](#)

Please note that the transcript of the conference call will be uploaded on the company website in due course.

About Neuland Laboratories Limited

For over 4 decades, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 100 APIs and has filed over 950+ Regulatory filings in the US (67 active US DMFs), the European Union (EU) and other geographies. Its manufacturing facilities are inspected and approved by the U.S. FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI "SID &GP" Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001. For more information, visit www.NeulandLabs.com.

If you have any questions or require further information, please feel free to contact

IR Department at Neuland

Tel: +91 40 6761 1600

Email: ir@neulandlabs.com

Ravi Udeshi / Minakshi Machutre

EY IR

Email: ravi.udeshi@in.ey.com / Minakshi.machutre@in.ey.com